Tucatinib (TUC) is an orally available, reversible HER2-targeted small-molecule tyrosine kinase inhibitor (TKI) approved by the European Medicines Agency (EMA) for the treatment of HER2-positive BC after two HER2-directing therapies. The gene discussed is ERBB2; the disease is breast cancer.